Currently Viewing:
Newsroom
Currently Reading
What We're Reading: Novartis Therapy Lottery; Merck Ebola Vaccine Approval; California Cannabis Use
December 20, 2019 – AJMC Staff
What We're Reading: Pelosi Drug Bill; Sarepta's Second Chance; Mental Health Care
December 13, 2019 – AJMC Staff
Genetic Variant Causing Heart Failure in Patients of African Descent Largely Goes Undiagnosed
December 12, 2019 – Laura Joszt
Real-World Data Shows Substantial Burden of Cost, AEs for Patients With MCL
December 07, 2019 – Laura Joszt
Improvements in Survival for Patients With Severe Acute or Severe Chronic GVHD
December 01, 2019 – Laura Joszt
First-Line Use of Ruxolitinib and Dosing Modifications in Patients With Polycythemia Vera
November 29, 2019 – Laura Joszt
Cannabis Reduces Headache, Migraine Severity by Nearly Half, Study Shows
November 26, 2019 – Matthew Gavidia
New Treatment Approved for Rare Genetic Disorder, Acute Hepatic Porphyria
November 20, 2019 – Laura Joszt
FDA Approves First Treatment for Rare Blood Disorder, Beta Thalassemia
November 15, 2019 – Laura Joszt

What We're Reading: Novartis Therapy Lottery; Merck Ebola Vaccine Approval; California Cannabis Use

AJMC Staff
Novartis hopes to distribute Zolgensma, its pricey spinal muscular atrophy drug, via lottery; Merck receives FDA approval for its Ebola vaccine, Ervebo; a new law in California hopes to resurrect compassionate use cannabis programs.

Novartis' Zolgensma to Treat SMA Set for Distribution Via Lottery

At a price tag of $2.1 million for 1 dose, Novartis’ Zolgensma (onasemnogene abeparvovec), which the FDA approved in May, making it only the second medication approved to treat spinal muscular atrophy (SMA), is the world’s costliest drug. Now, the pharma giant’s AveXis division has created a controversial lottery for distributing 100 doses of the drug in 2020 in countries where it is not yet approved, according to Reuters. Every 2 weeks until their eligibility expires, babies will be entered into the drawing. TreatSMA, a British advocacy group, has voiced its hesitancy about the lottery, but is seeking additional input before releasing its official position. Biogen’s Spinraza (nusinersen) was the first drug approved to treat SMA, with a cost of $750,000 for the first dose and $375,000 for subsequent doses.

 

Merck’s Ebola Vaccine, Ervebo, Receives FDA Approval

Ervebo, Merck’s vaccine to treat Ebola, was approved by the FDA yesterday, according to Stat News, following a similar decision by the European Commission on November 11. The drug will be used as protection against Zaire ebolaviruses, which is the species of virus most frequently cited as the cause of an Ebola outbreak. It will likely be stockpiled by several countries to protect against potential bioterrism attacks and for emergency use in cases of an outbreak. In the current Ebola outbreak in the Democratic Republic of the Congo, 3350 have been infected with Ebola and 2220 have died. Merck has qualified for a tropical disease priority review voucher because of the vaccine, and it can use that to fast-track FDA review of a future drug.

 

New California Law Could Remove Tax on Compassionate-Use Cannabis

In 1996, California passed the Compassionate Use Act, allowing medicinal use of marijuana. However, Proposition 64 in 2016 legalized recreational marijuana use in the state, and the tax rate on cannabis—more than 38% in some cases—made the drug unaffordable for those who needed it most. SB-34 hopes to reverse that and prevent patients from turning to the black market by lessening the financial liability. Signed by Governor Gavin Newsom in October, the new law would remove the cultivation, retail, and excise taxes imposed on cannabis donated for compassionate use, according to Kaiser Health News, and allow patients with cancer, AIDS, and glaucoma to once again afford the usually expensive remedy they use to treat their disease symptoms.

Related Articles

FDA Approves Gene Therapy With $2.1M Price Tag for Spinal Muscular Atrophy in Pediatric Patients
Cannabis Risks and Benefits in Cancer Symptom Management: Much Remains Unknown
Creating a More Affordable Healthcare System Through Value-Based Contracting
Hope and Some Skepticism Whether Oncology Payment Models Will Work
Senate Confirms Hahn as New FDA Commissioner
 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up